Details

Autor(en) / Beteiligte

• MERCHANT, THOMAS E
• THELISSEN, GUILLAUME R.P
• W. DE GRAAF, P PETER
• OTTER, WILLEM DEN
• GLONEK, THOMAS

Titel

Clinical Magnetic Resonance Spectroscopy of Human Breast Disease

Ist Teil von

• Investigative radiology, 1991-12, Vol.26 (12), p.1053-1058

Ort / Verlag

United States: Lippincott-Raven Publishers

Erscheinungsjahr

1991

Quelle

MEDLINE

Beschreibungen/Notizen

• Merchant TE, Thelissen GRP, de Graaf PW, Den Otter W,Glonek T. Clinical magnetic resonance spectroscopy of human breast disease. Invest Radiol 19913261053–1059. Using image-guided volume-selection techniques, in vivo phosphorus-31 magnetic resonance (MR) spectroscopic profiles were obtained from 12 patients with malignant breast tumors, six patients with benign breast tumors, and nine volunteers with no underlying pathologic condition. Phosphatic metabolites identified in the spectral profiles included the phosphomonoesters (PME), inorganic phosphate (Pi), phosphodiesters (PDE), phosphorylated glycans (PG), phosphocreatine (PCr) and adenosine triphosphate (ATP). Based on the results of previous high-resolution ex vivo “P MR spectroscopic analyses of breast tissues, the resonance of PC was identified in malignant and benign breast tumors. Malignant tumors were found to have a significantly (P < .05) lower concentration of (PME + Pi) than normal breast parenchyma, and were distinguishablefrom both benign tumors and normal breast parenchymal tissue by significantly (P < .01) elevated levels of (PDE + PG). “P MR spectroscopy is the first technique potentially capable of differentiating among malignant breast tumors, benign breast tumors, and normal breast parenchymal tissues based on their in vivo phosphatic metabolic profiles.